Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: A case report

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 17-23

  Huang, Yiwu ^a   Hayes, Roberta L ^a   Wertheim, Shelley ^a   Arbit, Ehud ^a   Scheff, Ronald ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Glioblastoma; IL 2; Immunotherapy; Interleukin 2; LAK; Lymphokine activated killer cells; Malignant glioma; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; PROCARBAZINE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CATHETER; CELLULAR IMMUNITY; CONFERENCE PAPER; GLIOBLASTOMA; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; RADIOSURGERY; RECURRENT CANCER; REMISSION; RESERVOIR;

ADULT; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; RECURRENCE; SALVAGE THERAPY;

EID: 0034983496     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00120-2     Document Type: Conference Paper

References (38)

1. Primary central nervous system tumors: Advances in knowledge and treatment
2. Cancer Statistics, 1998
3. Improved long-term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
4. The chemotherapy of high-grade astrocytomas
5. Contemporary approaches to the treatment of malignant gliomas with radiation therapy
6. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma
7. Principles of cancer management: biologic therapy
8. Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells - a case report
9. The cellular immunotherapy of primary brain tumors
10. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
11. Intratumoral LAK cell and interleukin-2 therapy of human gliomas
12. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2
13. Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas
14. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2
15. Cellular Therapy of Brain Tumors: Clinical Trials
16. Immunotherapy of malignant gliomas
17. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells
18. In vitro killing of human glioblastoma by interleukin-2 activated autologous lymphocytes
19. Cytolytic effects of autologous lymphocyte-activated killer cells on organotypic multicellular spheroids of gliomas in vitro
20. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor
21. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients
22. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells
23. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report
24. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA
25. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma
26. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors
27. Adoptive immunotherapy in patients with malignant glioma
28. Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2
29. Interleukin-2 or autologous lymphokine activated killer cell treatment of malignant glioma: Phase I trial
30. Oligodendroglioma
31. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors
32. Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF
33. A loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
34. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
35. MRI of recurrent high-grade astrocytomas after intralesional immunotherapy
36. Imaging of gliomas
37. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer
38. Eosinophils and serum eosinophilic cationic proteins in interleukin-2 based immunotherapy for cancer